Market Overview:
The global cetuximab market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of head and neck cancer and metastatic colorectal cancer, rising demand for targeted therapies, and growing awareness about cetuximab. Based on type, the global cetuximab market is segmented into 100 mg/50 mL injection and 200 mg/100 mL injection. The 100 mg/50 mL injection segment is expected to account for the majority share of the global cetuximab market in 2018. This segment is also projected to grow at a higher CAGR than the 200 mg/100 mL injection segment during the forecast period. Based on application, the global cetuximab market is divided into head and neck cancer and metastatic colorectal cancer.
Product Definition:
Cetuximab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR). It is used in the treatment of various types of cancer, including colorectal cancer, head and neck cancer, and non-small cell lung cancer.
100 mg/50 mL Injection:
Cetuximab is a human monoclonal antibody that inhibits interleukin (IL) - 1, - 6, and tumor necrosis factor (TNF) - 1. It's used in the treatment of rheumatoid arthritis and Crohn’s disease. The drug received FDA approval for the treatment of these diseases in 2002.
200 mg/100 mL Injection:
200 mg/100 mL Injection is a prescription medicine used for the treatment of patients with multiple myeloma, lymphoma, and leukemia. It is also used in combination with other medicines to treat cancer. 200 mg/100 mL injection contains 200 mg of Rituximab and 100 m L of sterile water for injection. The product was approved by the U.
Application Insights:
Cetuximab is used for the treatment of various cancers, including head and neck cancer, metastatic colorectal cancer and other cancers. The head and neck cancer segment dominated the global market in terms of revenue in 2017 due to increasing incidence rates of this disease. According to data published by WHO, around 1 million new cases were reported worldwide in 2018. Cetuximab is FDA-approved for the treatment of oropharyngeal (tonsils &/or voice box) squamous cell carcinoma (OPSC), which includes tumors arising from tonsils or voice box area. It is also approved by U.
Regional Analysis:
North America dominated the global cetuximab market in 2017, with a revenue share of over 55.0%. This is due to the presence of key players such as Pfizer Inc. and AbbVie Inc., which are engaged in extensive R&D activities for cancer treatment options. Moreover, increasing incidence rates of head and neck cancers coupled with rising healthcare expenditure by government agencies are some other factors contributing toward growth in this region.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to growing awareness about available treatment options among patients along with rising disposable income levels resulting into improved access to quality medical care facilities leading towards better diagnosis and treatment outcomes leading to improved survival rate for patients suffering from cancer types including bladder, lung, breast etc.
Growth Factors:
- Increasing incidence of head and neck cancer: The incidence of head and neck cancer is increasing globally due to the changing lifestyle and dietary habits. This will drive the demand for cetuximab in the coming years.
- Growing awareness about cetuximab: There is growing awareness among physicians about the benefits of cetuximab therapy, which is likely to boost its demand in the near future.
- Rising number of clinical trials for cetuximab: A large number of clinical trials are being conducted for cetuximab across the globe, which is indicative of its potential as a therapeutic agent. This will fuel its growth in the coming years.
- Availability of generic versions: Several generic versions of cetuximab are available in different countries, which has helped to make it more affordable for patients suffering from head and neck cancer. This will further boost its demand in future years.. 5
Scope Of The Report
Report Attributes
Report Details
Report Title
Cetuximab Market Research Report
By Type
100 mg/50 mL Injection, 200 mg/100 mL Injection
By Application
Head and Neck Cancer, Metastatic Colorectal Cancer
By Companies
Eli Lilly, Merck
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
203
Number of Tables & Figures
143
Customization Available
Yes, the report can be customized as per your need.
Global Cetuximab Market Report Segments:
The global Cetuximab market is segmented on the basis of:
Types
100 mg/50 mL Injection, 200 mg/100 mL Injection
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Head and Neck Cancer, Metastatic Colorectal Cancer
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eli Lilly
- Merck
Highlights of The Cetuximab Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 100 mg/50 mL Injection
- 200 mg/100 mL Injection
- By Application:
- Head and Neck Cancer
- Metastatic Colorectal Cancer
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cetuximab Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cetuximab is a monoclonal antibody that blocks the activity of tumor necrosis factor alpha (TNF-α). Cetuximab is used to treat various types of cancer.
Some of the key players operating in the cetuximab market are Eli Lilly, Merck.
The cetuximab market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cetuximab Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cetuximab Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cetuximab Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cetuximab Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cetuximab Market Size & Forecast, 2020-2028
4.5.1 Cetuximab Market Size and Y-o-Y Growth
4.5.2 Cetuximab Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 100 mg/50 mL Injection
5.2.2 200 mg/100 mL Injection
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Head and Neck Cancer
6.2.2 Metastatic Colorectal Cancer
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cetuximab Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cetuximab Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 100 mg/50 mL Injection
9.6.2 200 mg/100 mL Injection
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Head and Neck Cancer
9.10.2 Metastatic Colorectal Cancer
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 100 mg/50 mL Injection
10.6.2 200 mg/100 mL Injection
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Head and Neck Cancer
10.10.2 Metastatic Colorectal Cancer
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 100 mg/50 mL Injection
11.6.2 200 mg/100 mL Injection
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Head and Neck Cancer
11.10.2 Metastatic Colorectal Cancer
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 100 mg/50 mL Injection
12.6.2 200 mg/100 mL Injection
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Head and Neck Cancer
12.10.2 Metastatic Colorectal Cancer
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 100 mg/50 mL Injection
13.6.2 200 mg/100 mL Injection
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Head and Neck Cancer
13.10.2 Metastatic Colorectal Cancer
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cetuximab Market: Competitive Dashboard
14.2 Global Cetuximab Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Eli Lilly
14.3.2 Merck
